Advanced SearchSearch Tips
The Inhibitory Effect of Nicotine on TNF-α Expression in Human Fetal Astrocytes
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
The Inhibitory Effect of Nicotine on TNF-α Expression in Human Fetal Astrocytes
Son, Il-Hong; Lee, Sung-Ik; Yang, Hyun-Duk; Han, Sun-Jung; Suk, Seung-Han; Lee, Jai-Kyoo; Kim, Jae-Hyun; Park, Joo-Young; Moon, Hyung-In; Lee, Sung-Soo;
  PDF(new window)
The Tumor necrosis factor-α, (TNF-α), is involved in the pathogenesis of multiple sclerosis and contributes to the degeneration of oligodendrocytes as well as neurons. Nicotine has been found to have immunosuppressive and inflammation-suppressing effects. Astrocytes, the major glial cells in the CNS, are capable of producing TNF-α at both the mRNA and protein levels in response to interleukin-1 (IL-1) or TNF-α. Nicotine has been shown to influence glial cell functions. To order to explore the role of astrocytes in the production of TNF-α, astrocytes were pretreated with nicotine and are stimulated with IL-1β to determine their effects on TNF-α production. The results are as follows. Cytotoxic effects of nicotine on human fetal astrocytes were noted above 10 μg/ml of nicotine. The effect of IL-1β on TNF-α mRNA expression in primary cultured human fetal astrocytes was maximal at 2 h after IL- 1β(100 pg/ml) treatment. Human fetal astrocytes were pretreated with 0.1, 1, and 10 μg/ml of nicotine and then stimulated with IL-1β (100 pg/ml) for 2 h. The inhibitory effect of nicotine on expressions of TNF-α mRNA in human fetal astrocytes with pretreated 0.1 μg/ml of nicotine is first noted at 8 hr, and the inhibitory effect is maximal at 12 h. The inhibitory effect at 1 μg/ml of nicotine is inhibited maximal at 24 h. Nicotine at 0.1, 1 and 10 μg/ml concentrations significantly inhibits IL-1β-induced NF-κB activation. Collectively, this study indicates that nicotine might inhibit the expression of TNF-α in activated human fetal astrocytes.
TNF-;Human fetal astrocytes;nicotine;NF-;
 Cited by
Holt, P. G.; Keast, D. E. Bacteriol Rev 1977, 41, 205

Motley, R. J.; Rhodes. J.; Williams, G. J Pharm Pharmacol 1990, 42, 288 crossref(new window)

Sugano, N.; Shimada, K, Ito, K. BBRC 1998, 252, 25

Baron, J. A. Br Med Bull 1996, 52, 58 crossref(new window)

Haas, L. F. J Neurol Neurosurg Psychiatry. 1992, 55, 430 crossref(new window)

Dignam, J. D.; Lebovitz, R. M.; Roeder, R. G. Nucl Acids Res 1983, 11, 1475 crossref(new window)

Bradford, M. M. Anal Biochem 1976, 72, 248 crossref(new window)

Wang, C. Y.; Mayo, M. W.; Baldwin, A. S. Science 1996, 274, 784

Tamatani, M.; Che, Y.H.; Matsuzaki, H. J Biol Chem 1999, 274, 8531 crossref(new window)

Baldwin, A.S. Annu Rev Immunol 1996, 14, 649 crossref(new window)

Ghosh, S.; May, M. J.; Kopp, E. B. Annu Rev Immunol 1998, 16, 225 crossref(new window)

Van Antwerp, D. J.; Martin, S. J.; Kafri, T. Science 1996, 274, 787

Aoyuki, S.; Koichi, S.; Koichi, I. BBRC 1998, 252, 25

Benveniste, E. N.; Tang, L. P.; Law, R. M. Int J Dev Neurosci 1995, 13, 341 crossref(new window)